# Amgen Q3 Revenue Hits $10.4 Billion

> Amgen's Q3 revenue reaches $10.4 billion with 8% growth from key products.
- Title: Amgen Q3 Revenue Hits $10.4 Billion · Pulse 2.0 | Shortify
- Summary: Amgen's Q3 revenue reaches $10.4 billion with 8% growth from key products. Amgen reported $10.4 billion in Q3 2026 revenue, an 8% year-over-year increase…
- Keywords: amgen, repatha, uplizna, q3 revenue, 8% growth, biotech company, Pulse 2.0
- Source: Pulse 2.0 — https://pulse2.com/amgen-10-4-billion-q3-revenue-reflects-8-growth-as-repatha-uplizna-and-imdelltra-sales-accelerate
- Author: Amit Chowdhry
- Published: 2026-11-06T13:56:08+00:00
- Read time: 1 min
- Topics: amgen, repatha, uplizna, q3 revenue, 8% growth, biotech company, startups, business
## Amgen Reports Q3 2026 Revenue
Amgen reported third-quarter 2026 revenue of $10.4 billion, an 8% increase from the prior-year period.
## Key Products Drive Growth
Repatha, EVENITY, UPLIZNA, TEZSPIRE, and IMDELLTRA sales accelerated, contributing to the 8% year-over-year increase.
## GAAP Earnings Boost
GAAP earnings per share increased 19% to $7.08 from $5.93 in Q3 2025, with operating income at $3.7 billion.
## Non-GAAP Results
Non-GAAP earnings per share rose 14% to $6.45, with operating income at $4.7 billion.
## Repatha Sales Surge
Repatha generated $1.085 billion in quarterly sales, a 37% year-over-year increase driven by higher patient demand.
## UPLIZNA and Rare Disease Growth
UPLIZNA sales rose 191% year-over-year to $451 million, while KRYSTEXXA revenue increased 31% to $419 million.
## Key takeaway

Amgen reported $10.4 billion in Q3 2026 revenue, an 8% year-over-year increase driven by Repatha, UPLIZNA, and IMDELLTRA sales.